Akers Biosciences Completes Clinical Trial for Rapid Chlamydia Test
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Akers Biosciences (AKER) Shares Pop Higher Upon Completion of PIFA/Chlamydia Rapid Assay Clinical Trial
June 30, 2016 9:00 AM EDTAkers Biosciences (Nasdaq: AKER) shares are popping higher in early trading after the company announced that it completed a clinical trial of its PIFA/Chlamydia Rapid Assay, the first rapid test for Chlamydia diagnosis using a finger stick blood sample.
Akers is up over 17 percent ahead of the opening bell.
... More